ETBF is a subtype of Bacteroides fragilis that carries the gene for Bacteroides fragilis toxin, known as BFT. The bacterium has been linked to diarrheal disease, inflammatory bowel disease and colorectal cancer, and colonization is known to be associated with long-term disturbances of intestinal motility. What remained unclear was precisely how a toxin famous for cleaving epithelial junctions could leave the gut’s movement machinery permanently impaired. The Shanghai team approached the question using mouse colonization models in which animals were inoculated with ETBF and followed over weeks, allowing the researchers to track both the microbial load and the structural integrity of the colonic myenteric plexus, the network of neurons embedded in the gut wall that orchestrates peristalsis.

The answer was stark. ETBF colonization triggered the loss of colonic myenteric neurons, and the effect depended entirely on BFT: mice colonized with a genetically engineered ETBF strain lacking the bft gene were largely protected. The toxin did not merely stun the neurons; it drove them into apoptosis, a programmed cell death routine. Critically, the neuronal loss and the accompanying motility dysfunction persisted even after the bacteria themselves had been cleared from the gut, a finding that echoes the clinical phenomenon of post-infectious gut disorders, in which symptoms linger long after the offending pathogen has disappeared. The researchers measured this dysfunction using gastrointestinal transit time and ex vivo recordings of colonic strip contractions, both of which deteriorated in colonized animals.

Having established that BFT kills enteric neurons, the team dissected the molecular pathway inside the cells. The toxin’s lethal signal, they found, runs through NOD1, an intracellular pattern-recognition receptor, which recruits its adaptor protein RIPK2 and then activates a caspase cascade: caspase-9, the initiator of the intrinsic apoptotic pathway, followed by caspase-3, the executioner. When the researchers knocked out Nod1 in mice, the BFT-induced neuronal apoptosis and dysmotility were markedly attenuated, confirming that this receptor, better known for sensing bacterial peptidoglycan and driving inflammatory responses, also functions as a death switch in enteric neurons when provoked by BFT. The pathway is notable because NOD1 has previously been identified as a functional receptor for BFT in cancer contexts, suggesting the toxin may have co-opted a host surveillance system for destructive purposes across multiple cell types.

The second half of the study addresses a question that has intrigued microbiome researchers for years: why do ETBF and Fusobacterium nucleatum so often appear together in diseased guts? Analyses of patient cohorts with inflammatory bowel disease and colorectal cancer revealed a positive correlation between the abundance of the two organisms, hinting at a cooperative rather than coincidental relationship. To test this directly, the researchers co-colonized mice with both species. The result was dramatic: the presence of F. nucleatum significantly aggravated the ETBF-induced loss of myenteric neurons and worsened gut dysmotility, and the effect again required bft, indicating that the oral pathobiont was not adding its own toxin but rather turning up the volume on ETBF’s.

The mechanism behind this microbial collusion proved to be a small molecule. F. nucleatum produces 2-hydroxybutyric acid, or 2HB, a metabolite generated through lactate dehydrogenase activity. When ETBF is exposed to 2HB, the toxin gene bft is transcribed at far higher levels. The team showed that 2HB physically binds to RprY, a regulatory protein in ETBF that normally represses bft transcription. By occupying RprY, the metabolite lifts this repression, derepressing the toxin gene without altering other virulence genes controlled by the regulator. In other words, one bacterium’s metabolic waste product acts as a molecular key that unlocks another bacterium’s most dangerous weapon. Administering 2HB to mice colonized with ETBF alone reproduced the aggravating effect, while F. nucleatum strains engineered to overproduce the metabolite intensified neurotoxicity further, and the researchers confirmed that multiple F. nucleatum subspecies produce 2HB in culture.

The clinical implications extend beyond motility. The study found that the enteric neuron loss and dysmotility induced by ETBF increased susceptibility to dextran sulfate sodium-induced colitis in mice, linking the neural damage to a weakened mucosal defense. This connects with a growing body of evidence that the enteric nervous system is not merely a passive conduit for brain signals but an active participant in intestinal immunity and barrier maintenance. Previous work has shown that other pathogens, from Shigella to Clostridioides difficile, can target enteric neurons, and that neuronal loss in conditions such as Chagas disease and Hirschsprung disease produces profound motility defects. The new study adds a bacterial cooperation model to this landscape, in which the composition of the microbiome determines how much toxin a colonizing pathogen actually delivers.

Human relevance was reinforced by tissue analyses. In colonic specimens from ulcerative colitis patients, the researchers detected the bft gene in mucosal tissue and observed myenteric neurons positive for NOD1, RIPK2, cleaved caspase-9 and cleaved caspase-3, the same molecular signature seen in the mouse model, with the staining pattern more prominent in patients suffering from constipation. While such observational data cannot prove causation in humans, the concordance between the animal pathway and the human tissue findings strengthens the case that the mechanism operates in clinical disease.

Perhaps the most immediately actionable finding concerns therapy. The researchers tested Bifico, a commercially available probiotic formulation containing Bifidobacterium species, in their mouse model. Treatment attenuated the neuronal toxicity, improved intestinal motility and reduced the severity of subsequent colitis. Bifidobacterium longum alone recapitulated much of the protective effect, and the probiotic did not simply eradicate ETBF; rather, it appeared to interfere with the processes that drive toxin production and neuronal death. Given that probiotics are inexpensive, widely available and generally safe, the finding suggests a plausible strategy for preventing the long-term neurological consequences of ETBF colonization, although the authors and independent observers caution that mouse models do not always translate to human therapy and that controlled clinical trials would be needed.

The study, published in Nature Microbiology with the DOI 10.1038/s41564-026-02497-y, is likely to resonate across several fields at once. For microbiome researchers, it provides a textbook example of metabolic cross-feeding with pathological consequences, in which a diffusible small molecule from one species reprograms virulence gene expression in another. For neurogastroenterologists, it identifies a specific toxin-receptor-caspase axis that destroys the neurons governing bowel movement, offering potential drug targets in NOD1, RIPK2 or the caspases themselves. And for clinicians treating patients with post-infectious bowel dysfunction, irritable bowel symptoms or inflammatory bowel disease, it raises the possibility that screening for ETBF and F. nucleatum co-colonization, and perhaps manipulating the microbiome to reduce 2HB production or boost protective Bifidobacterium, could one day prevent the slow, silent loss of the gut’s own nervous system. The data and bacterial strains underlying the work have been deposited in public repositories, including a Zenodo archive of the neuronal RNA-sequencing data, allowing other laboratories to build on the findings immediately.

Subject of Research: Bacterial cooperation between Fusobacterium nucleatum and enterotoxigenic Bacteroides fragilis in enteric neuron loss and intestinal dysmotility

Article Title: Fusobacterium nucleatum enhances enterotoxigenic Bacteroides fragilis-mediated neuron loss and intestinal motility dysfunction

Article References: Zhang, Y., Zhao, Y., Zhang, L., Xuan, B., Wang, Z., Yu, B., Li, W., Huang, X., Zhou, Y., Ning, L., Ding, J., Jiang, Y., Hu, M., Shao, Y., Li, L., Gao, X., Chen, S., Chen, H., Wang, F., … Hong, J. (2026). Fusobacterium nucleatum enhances enterotoxigenic Bacteroides fragilis-mediated neuron loss and intestinal motility dysfunction. Nature Microbiology. https://doi.org/10.1038/s41564-026-02497-y

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02497-y

Keywords: Fusobacterium nucleatum, enterotoxigenic Bacteroides fragilis, Bacteroides fragilis toxin, enteric nervous system, gut dysmotility, 2-hydroxybutyric acid, NOD1, apoptosis, gut microbiota, inflammatory bowel disease, probiotics, Bifidobacterium

The foundational concept behind this research is the recognition of oncomicrobes—specific microorganisms that contribute to tumor development. A growing body of evidence indicates that certain gut bacteria, when in excess, can foster an inflammatory environment conducive to cancer progression. This study posits that by employing vaccines targeting these oncomicrobes, a powerful tool can be forged not only to mitigate tumor development but also to preserve the integrity of the beneficial gut microbiota that play essential roles in overall health.

Central to this study were two experimental mouse models. The first model focused on preventive strategies targeting the oncomicrobe Campylobacter jejuni, known for its pathogenic impact and association with CRC. The second model turned its attention towards Enterotoxigenic Bacteroides fragilis (ETBF), which has been identified as a significant contributor to CRC pathogenesis. Researchers meticulously developed and administered vaccines specific to each microbial target, aiming to demonstrate that induction of robust immune responses could effectively inhibit tumorigenesis.

Impressive findings emerged when the vaccine against C. jejuni demonstrated a marked reduction in the incidence of tumors among treated mice. This protective effect was accompanied by rapid clearance of the oncomicrobe from the gut, indicating not just a preventive but potentially therapeutic benefit as well. This result reinforces the potential of targeting specific microbial agents to inhibit cancer development effectively.

In the therapeutic context, the ETBF vaccine presented compelling evidence of efficacy. Tumor numbers significantly declined among vaccinated mice, and a notable restoration of beneficial gut bacteria was observed. Specifically, the abundance of non-toxic strains of Bacteroides fragilis increased, suggesting that the vaccine not only suppresses harmful microbial populations but also restores a healthier microbial balance. This dual-action presents a promising paradigm in CRC management, marrying tumor suppression with microbiota restoration.

A critical concern in the development of microbial-targeted therapies is the potential disruption of the gut microbiota—a delicate ecosystem essential for maintaining health. Remarkably, both vaccines demonstrated minimal disruption to the overall gut microbiota composition, suggesting a targeted approach that spares beneficial bacteria while eliminating pathogenic strains. This specificity is a cornerstone of effective immunotherapy, as it minimizes unintended consequences associated with more aggressive treatments, such as antibiotics.

The immune response elicited by these vaccines is noteworthy. Enhanced levels of antibodies and activated T cells played pivotal roles in tumor suppression. This finding underscores the importance of a well-coordinated immune attack against not just the tumor itself but the microbial agents that facilitate its growth and progression. The study highlights the potential for vaccination to prime the immune system to respond more vigorously when faced with tumor development.

Moreover, the vaccines appeared to influence the intestinal metabolome, which is the collection of metabolites produced by gut microbes. The vaccine targeting C. jejuni led to an increase in beneficial antitumor metabolites, accompanied by a decrease in those promoting tumor growth. This suggests that beyond direct action on microbes, these vaccines may modulate the broader metabolic landscape of the gut, creating an environment less conducive to cancer development.

Despite the promising data generated from this mouse study, translating these findings into effective human therapies requires caution and further investigation. Trials involving human subjects will be crucial in assessing the safety and effectiveness of such treatments. Yet, the implications of this research are profound. If validated in clinical settings, these vaccines could represent a groundbreaking addition to the current strategies employed in CRC prevention and treatment.

A significant aspect of this research is its focus on high-risk populations. Many individuals carry higher susceptibilities to CRC due to genetic predispositions or specific lifestyle risk factors. By tailoring vaccines to target the oncomicrobes prevalent in these high-risk groups, medical professionals could establish preventive strategies that are both innovative and effective.

In conclusion, the research surrounding oncomicrobial vaccines targeting C. jejuni and ETBF marks a significant advancement in the fight against colorectal cancer. The study offers a glimpse into the future of cancer immunotherapy, where vaccines do not just bolster immune defenses but specifically construct an environment that fosters health by targeting known threats. Further exploration and clinical application of these findings may revolutionize the preventive and therapeutic approaches to one of the most formidable cancers affecting global populations today.

Ultimately, the movement towards personalized and microbial-focused immunotherapies appears poised to reshape cancer treatment paradigms. The prospect of vaccines that target specific microbes, mitigate inflammation, and maintain microbial diversity heralds an exciting new era in our ongoing battle against cancer. As research progresses, continual adaptation and innovation within this field will be essential, positioning oncomicrobial vaccines as a beacon of hope in cancer prevention and therapy.

Subject of Research: Animals
Article Title: Oncomicrobial vaccines mitigate tumor progression via precisely targeting oncomicrobes in mice
News Publication Date: 7-Jan-2025
Web References: Protein & Cell
References: DOI link
Image Credits: Yudan Mao, Yan Li, Xianzun Xiao, Junrui Mai, Gan Lin, Sheng Liu, Jiayuan Huang, Xiangting Zhou, Xiangyu Mou, Wenjing Zhao
Keywords: Oncomicrobes, Colorectal Cancer, Vaccines, Immunotherapy, Gut Microbiota, Cancer Prevention, Tumor Suppression, Antibody Response, Metabolome, Therapeutic Models.